Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis

Journal of Clinical Pharmacology

Volumn 47, Issue 3, 2007, Pages 383-396

  Zhou, Honghui ^a   Jang, Haishan ^a   Fleischmann, Roy M ^b   Bouman Thio, Esther ^a   Xu, Zhenhua ^a   Marini, Joseph C ^a   Pendley, Charles ^a   Jiao, Qun ^a   Shankar, Gopi ^a   Marciniak, Stanley J ^a   Cohen, Stanley B ^b   Rahman, Mahboob U ^a   Baker, Daniel ^a   Mascelli, Mary Ann ^a   Davis, Hugh M ^a   Everitt, Daniel E ^a  

^a CENTOCOR INC   (United States)

^b RADIANT RESEARCH   (United States)

Author keywords

Golimumab; Human anti TNF monoclonal antibody (mAb); Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847167546     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006298188     Document Type: Article

References (17)

1. Beutler B. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York: Raven Press ; 1992.
2. Brennan FM, Maini RN, Feldmann M. TNF alpha - a pivotal role in rheumatoid arthritis ? Br J Rheumatol. 1992 ; 31: 293-298.
3. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001 ; 33: 251-255.
4. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992 ; 339: 89-91.
5. Russo C, Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond). 2005 ; 109: 135-142.
6. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994 ; 56: 248-252.
7. US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Population Pharmacokinetics. Rockville, Md: US Department of Health and Human Services ; 1999.
8. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr. 1993 ; 6: 1248-1257.
9. Westhovens R, Houssiau F, Joly J, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J Rheumatol. 2006 ; 33: 847-853.
10. Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006 ; 26: 813-827.
11. Velagapudi RB, Noertersheuser PA, Awni WM, et al. Effect of methotrexate (mtx) coadministration on the pharmacokinetics (pk) of adalimumab (Humira, Abbott) following a single intravenous (iv) injection. Arthritis Rheum. 2003 ; 48: S141 - S141.
12. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 ; 93: 2645-2668.
13. Roshammar D, Hai TN, Friberg Hietala S, Van Huong N, Ashton M. Pharmacokinetics of piperaquine after repeat oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol. 2006 ; 62: 335-341.
14. Takama H, Tanaka H, Sudo T, Tamura T, Tanigawara Y. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase I study. Cancer Chemother Pharmacol. 2001 ; 47: 404-410.
15. Zhou H, Khalilieh S, Lau H, et al. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol. 1999 ; 39: 911-919.
16. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modeling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol. 1999 ; 47: 53-58.
17. Launay-Iliadis MC, Bruno R, Cosson V, et al. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol. 1995 ; 37: 47-54.